{"id":2194,"date":"2011-11-01T12:00:00","date_gmt":"2011-11-01T11:00:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2011\/pay-for-performance-programm-fuer-bevacizumab-bei-patienten-mit-fortgeschrittener-krebserkrankung-innovatives-oder-unserioeses-angebot"},"modified":"2011-11-01T12:00:00","modified_gmt":"2011-11-01T11:00:00","slug":"pay-for-performance-programm-fuer-bevacizumab-bei-patienten-mit-fortgeschrittener-krebserkrankung-innovatives-oder-unserioeses-angebot","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2011\/pay-for-performance-programm-fuer-bevacizumab-bei-patienten-mit-fortgeschrittener-krebserkrankung-innovatives-oder-unserioeses-angebot","title":{"rendered":"\u201ePay for Performance\u201d-Programm f\u00fcr Bevacizumab bei Patienten mit fortgeschrittener Krebserkrankung: Innovatives oder unseri\u00f6ses Angebot?"},"content":{"rendered":"<p>Bevacizumab (Avastin\u00ae), ein humanisierter, gegen den Vascular Endothelial Growth Factor (VEGF) gerichteter monoklonaler Antik\u00f6rper, wurde nach seiner Zulassung in Kombination mit Zytostatika oder Zytokinen f\u00fcr die Erstlinientherapie verschiedener fortgeschrittener solider Tumore vom Hersteller Roche Pharma AG rasch als \u201ePan-Tumor-Medikament\u201d angepriesen. Inzwischen hat dieser Antik\u00f6rper vermutlich den Zenit der weltweit Milliarden-hohen Ums\u00e4tze (in den USA 2009: [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bevacizumab (Avastin\u00ae), ein humanisierter, gegen den Vascular Endothelial Growth Factor (VEGF) gerichteter monoklonaler Antik\u00f6rper, wurde nach seiner Zulassung in Kombination mit Zytostatika oder Zytokinen f\u00fcr die Erstlinientherapie verschiedener fortgeschrittener solider Tumore vom Hersteller Roche Pharma AG rasch als \u201ePan-Tumor-Medikament\u201d angepriesen. Inzwischen hat dieser Antik\u00f6rper vermutlich den Zenit der weltweit Milliarden-hohen Ums\u00e4tze (in den USA 2009: [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[255,2156,711,146,4216,2374,430,771,772,1205,149,2229,257,1177,4389,4390,3157,1143,4214,4388,1561],"class_list":["post-2194","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-arzneimittel","tag-bevacizumab","tag-bronchialkarzinom","tag-brustkrebs","tag-cost-sharing-initiativen","tag-kliniken","tag-kolonkarzinom","tag-krankenhaus","tag-krankenhaeuser","tag-krankenkassen","tag-mammakarzinom","tag-marketing","tag-medikamente","tag-nierenzellkarzinom","tag-p4p","tag-pay-for-performance-programm","tag-rabattvertraege","tag-rektumkarzinom","tag-risk-share-vertraege","tag-roche-pharma-ag","tag-werbung"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2194","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=2194"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2194\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=2194"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=2194"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=2194"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}